INTerpath-001: AI Accelerates Personalized Cancer Medicine in Melanoma

Artificial intelligence (AI) and personalized immunotherapy are taking an important step forward in precision oncology. The Phase III INTerpath-001 trial met both of its efficacy endpoints: recurrence-free survival (RFS) and distant metastasis-free survival (DMFS).

The study enrolled 1,137 patients with completely surgically resected stage IIB–IV cutaneous melanoma. The combination of intismeran autogene (V940/mRNA-4157), an investigational personalized mRNA therapy, and pembrolizumab demonstrated statistically significant and clinically meaningful benefits compared with pembrolizumab alone, according to preliminary results announced by Merck and Moderna.

What is AI’s contribution? Machine learning algorithms and bioinformatics tools support the identification and selection of promising tumor neoantigens, helping to design an mRNA-based therapy tailored to the molecular characteristics of each patient’s tumor.

It is important to note that the full quantitative results were not yet available in the initial announcement, and overall survival remains under evaluation.

The integration of AI, bioinformatics, mRNA technology, and immunotherapy opens up promising prospects for increasingly personalized cancer treatment.

References

1. Merck & Moderna. INTerpath-001: preliminary Phase III results, August 19, 2026.

2. The ASCO Post. “INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints,” August 21, 2026.

3. ClinicalTrials.gov. INTerpath-001, NCT05933577.

Referenze

1. Merck & Moderna. INTerpath-001: risultati preliminari di fase III, 19 agosto 2026.

2. The ASCO Post. INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints, 21 agosto 2026.

3. ClinicalTrials.gov. INTerpath-001, NCT05933577.